Catalyst Pharmaceuticals, Inc. (CPRX)
NASDAQ: CPRX · IEX Real-Time Price · USD
15.80
+0.03 (0.19%)
At close: Jul 2, 2024, 4:00 PM
15.63
-0.17 (-1.08%)
After-hours: Jul 2, 2024, 7:59 PM EDT
Catalyst Pharmaceuticals Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for CPRX stock have an average target of 27.8, with a low estimate of 23 and a high estimate of 34. The average target predicts an increase of 75.95% from the current stock price of 15.80.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for CPRX stock from 5 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jan '24 | Feb '24 | Mar '24 | Apr '24 | May '24 | Jun '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 4 | 4 | 4 | 3 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 6 | 6 | 6 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Oppenheimer | Oppenheimer | Buy Reiterates $29 | Buy | Reiterates | $29 | +83.54% | Jun 6, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $26 | Strong Buy | Reiterates | $26 | +64.56% | Jun 3, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $24 → $26 | Strong Buy | Maintains | $24 → $26 | +64.56% | May 10, 2024 |
| Oppenheimer | Oppenheimer | Buy Reiterates $29 | Buy | Reiterates | $29 | +83.54% | Mar 27, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $34 | Buy | Reiterates | $34 | +115.19% | Mar 22, 2024 |
Financial Forecast
Revenue This Year
470.71M
from 398.20M
Increased by 18.21%
Revenue Next Year
553.69M
from 470.71M
Increased by 17.63%
EPS This Year
1.10
from 0.63
Increased by 74.86%
EPS Next Year
1.48
from 1.10
Increased by 34.26%
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 490.1M | 602.4M | 746.6M | 925.1M | 737.0M |
| Avg | 470.7M | 553.7M | 643.6M | 730.0M | 689.1M |
| Low | 446.3M | 514.1M | 538.6M | 597.1M | 636.3M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 23.1% | 28.0% | 34.8% | 43.7% | 1.0% |
| Avg | 18.2% | 17.6% | 16.2% | 13.4% | -5.6% |
| Low | 12.1% | 9.2% | -2.7% | -7.2% | -12.8% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 1.54 | 2.10 | 1.99 | 4.10 | 2.80 |
| Avg | 1.10 | 1.48 | 1.65 | 3.24 | 2.72 |
| Low | 0.88 | 1.23 | 1.33 | 2.40 | 2.62 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 145.0% | 90.6% | 34.9% | 147.8% | -13.4% |
| Avg | 74.9% | 34.3% | 11.7% | 96.0% | -15.9% |
| Low | 40.0% | 11.2% | -9.9% | 45.3% | -19.2% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.